Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 7.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,600 shares of the medical equipment provider's stock after selling 5,900 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in Zimmer Biomet were worth $8,556,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of ZBH. Menard Financial Group LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $30,000. Accredited Wealth Management LLC purchased a new stake in shares of Zimmer Biomet during the fourth quarter worth about $36,000. OFI Invest Asset Management acquired a new position in shares of Zimmer Biomet during the 4th quarter worth about $40,000. Dunhill Financial LLC boosted its holdings in Zimmer Biomet by 86.6% in the 4th quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider's stock worth $47,000 after buying an additional 206 shares during the last quarter. Finally, SRS Capital Advisors Inc. increased its stake in Zimmer Biomet by 146.9% during the 4th quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider's stock worth $51,000 after buying an additional 285 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock traded up $0.67 during trading on Friday, reaching $91.22. The company's stock had a trading volume of 3,979,902 shares, compared to its average volume of 1,802,903. The firm has a market cap of $18.05 billion, a PE ratio of 20.18, a P/E/G ratio of 2.09 and a beta of 0.72. The company has a 50-day moving average price of $95.51 and a two-hundred day moving average price of $102.99. The company has a current ratio of 2.44, a quick ratio of 1.46 and a debt-to-equity ratio of 0.53. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The business had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. During the same quarter in the prior year, the firm earned $1.94 earnings per share. The business's quarterly revenue was up 1.1% compared to the same quarter last year. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.05%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's payout ratio is 21.24%.

Analyst Ratings Changes

ZBH has been the subject of a number of research reports. Morgan Stanley dropped their target price on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. JMP Securities lowered their price target on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. Robert W. Baird decreased their target price on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Stifel Nicolaus set a $115.00 price target on Zimmer Biomet and gave the company a "buy" rating in a research report on Tuesday, May 6th. Finally, Canaccord Genuity Group reduced their price objective on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $111.53.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 1,000 shares of the business's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the sale, the insider now owns 20,424 shares of the company's stock, valued at $1,940,280. The trade was a 4.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.39% of the stock is owned by corporate insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.